Pfizer and its German partner BioNTech are planning to offer the first dose of its investigational COVID-19 vaccine by March 1, 2021 to those volunteers who received a placebo in its vaccine trial, Reuters reported. Notably, Pfizer (PFE) and BioNTech’s investigational COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA). However, on Dec. 11, the U.S. FDA authorized Pfizer-BioNTech to provide the investigational vaccine for emergency use in individuals aged 16 years and older.